What Is Spinal Muscular Atrophy?
An Essay on Anterior Horn Cells, the Household as Control Group, and the Testimony That Made Both Visible
Author’s Note
This essay operates in two registers. When examining establishment epidemiology, genetic claims, and pharmaceutical trial data, it uses establishment terminology to prosecute the establishment’s own case against itself. When stating what is actually happening in the body, it shifts to terrain language. The reader should know which voice is operating: the former demonstrates that the cause is not unknown to those who have looked; the latter explains what they found.
The essay draws on the recorded testimony of Cyndi Peterson, a physician whose two daughters, Kelly and Sarah, were diagnosed with spinal muscular atrophy in the early 2000s and died before their second birthdays. Her testimony arrives with a Catholic-faith framework offered to her precisely because the medical framework had nothing to give her. Separating what is documented (her daughters died) from the story built on that fact (they died of a genetic disorder) does not require dismissing the faith dimension. The faith dimension is hers and stands on its own axis. The medical dimension is what this essay examines.
The Diagnosis
Cyndi Peterson was a physician in private practice, married to a physician, mother of three healthy boys. She had spent ten years in the Navy as a flight surgeon before entering practice.¹ Her fourth child was a girl. Kelly was born late 1999 or early 2000. She was a quiet baby who was not lifting her head, not sitting up, not moving her arms or legs the way her older brothers had at the same age. By four and a half months her mother could no longer explain the delay away as constitutional.
The pediatric neurologist ran the blood test. Two weeks later she called both parents into the office. The diagnosis was spinal muscular atrophy. The neurologist told them that both parents carried the deletion, that carrier frequency ran at approximately one in eighty (the establishment-cited figure is higher, one in forty to one in sixty), and that only one pregnancy in four would produce an affected child.¹ The mother, herself a physician, asked what the treatment was. The answer was that there was none. The disorder was 100% fatal. Average lifespan for Type 1 was nine months. Kelly was five.
Kelly went to Medjugorje in her mother’s arms. She came home on a flight in which the mother believed she was dying in mid-air. She survived to be admitted to the ICU. She was discharged home to hospice care because the hospital had nothing more to offer. She died in her mother’s arms.
A few years later the mother chose to have another child. She got pregnant immediately. She named the child Sarah. Sarah was strong at birth, stronger, her mother said, than any of her three brothers.² A cord-blood sample was drawn to test for the disorder. The lab reported the sample contaminated and asked the parents to bring Sarah back for a heel-stick. The second test returned the same finding: two copies of the deleted SMN1 gene, homozygous, the same diagnosis as her sister. Sarah, still visibly strong at that point, was declared to have an incurable fatal disease before her third month.
What happened next is where the medical model and the terrain model diverge. The mother went on a retreat in Croatia with Father Zlatko Sudac. She began a forty-day water fast. She prayed intensively. Sarah, over the following six months, gained strength. She kicked her mother. She moved her arms. She began to sit up. She began to take solid food. For six months she trended upward. Then, over the following six months, she declined. She went into the hospital, had a feeding tube placed, returned home, and died in her mother’s arms. She lived, in her mother’s account, “exactly one year longer than expected.”² A child with a nine-month prognosis had lived to approximately twenty-one months, with six months of that lifespan marked by clinically visible reversal of the exact motor deficits the diagnosis was defined by.
Two daughters. One diagnosis. Three older brothers who never developed a symptom. A mother who was a physician with a decade of military occupational exposure. A father who was a physician. Everything about the case sits on the record. What the case reveals depends on which framework the reader brings to it.
This work stays free because paid subscribers make it possible. They get the full book library, the Deep Dive Audio Library, and the Questions for Your Doctor, Before You Consent, and Package Insert series. No grants, no gatekeepers — your subscription is what keeps it that way.
Audio Deep Dive (for Paid Subscribers)
In Print
Two of my books are now available as paperbacks. The Unvaccinated: What a Forbidden Comparison Reveals About the True Cost of Vaccination is, as far as I know, the only book of its kind — the completely unvaccinated as a comparison group, laid out across twenty chapters and five appendices. Alongside it is Medicalized Motherhood: From First Pill to Permanent Patient, which follows a woman through 123 documented interventions from teenage pill to postpartum discharge. Both are printed to order through Lulu, shipped worldwide, USD $19.99 each. A physical book reaches the person a Substack post never will — the sceptical relative, the friend who won’t click a link but might open a book, the visitor whose eye lands on a coffee table. Buy one to keep, and one to give away.
What the Establishment Says
Guido Werdnig described the first cases of severe infantile motor neuron degeneration in 1891.³ Johann Hoffmann described a further series in 1893. The condition their names still label, Werdnig-Hoffmann disease or Type 1 spinal muscular atrophy, is the pediatric parallel of what Jean-Martin Charcot had named amyotrophic lateral sclerosis for adults twenty-two years earlier. Both conditions kill the same population of cells: the anterior horn motor neurons of the spinal cord, and the corresponding neurons of the brainstem and motor cortex. Both produce progressive weakness, feeding failure, respiratory failure. The pediatric version arrives before development completes. The adult version arrives after decades of exposure have accumulated. The cell death is the same. The timeline compresses in the child.
A hundred and four years after Werdnig’s original description, in 1995, Judith Melki’s laboratory in Paris identified a gene on chromosome 5q13 whose deletion appeared in the DNA of most patients diagnosed with the condition. The gene was named the survival motor neuron gene, SMN1.⁴ A nearby paralog, SMN2, produced a shortened and mostly non-functional version of the same protein but retained the capacity to compensate partially when SMN1 was deleted. The number of SMN2 copies in the genome correlated inversely with disease severity: more copies, milder disease.
That is the framework as the establishment now presents it. Approximately ninety-five percent of clinical SMA cases are attributed to homozygous deletion of exon 7 of SMN1.⁴ The condition is described by mainstream sources as the second most common fatal autosomal recessive disorder after cystic fibrosis.⁵ Population incidence is cited as approximately one in six thousand to one in ten thousand live births. Carrier frequency runs at approximately one in forty to one in sixty in the general population.⁵ The clinical classification runs by age of onset: Type 1 (Werdnig-Hoffmann) presents before six months and never sits; Type 2 sits but never stands; Type 3 walks but declines; Type 4 presents in adulthood.
Where the framework closes off inquiry is the same place the framework for adult motor neuron disease closes off inquiry, and for the same reason. In the adult version the establishment concedes the cause is unknown for approximately ninety percent of cases, calling them “sporadic,” and attributes the remaining ten percent to inherited genetic mutations across four named genes that account for roughly seventy percent of that ten percent.⁶ Seven cases in a hundred are “explained.” The other ninety-three are left in the dark. In the pediatric version the framework claims better closure: SMN1 deletion is found in ninety-five percent of cases. But finding a gene variant correlated with the disease is not the same as finding a cause. The framework treats the correlation as sufficient. The mechanism by which the deletion produces the death of specific cells at specific ages under specific exposures is not addressed. The framework describes what is present in the cells that died. It does not explain why those particular cells die at that particular time in that particular child while a sibling with different exposure history does not develop the condition, even when carrying the same variants.
The next section is where that gap becomes visible.
The Missing Control Group
Cyndi Peterson gave birth to five children. Three boys came first. All three were, and are, healthy. The two girls followed. Both were diagnosed with Type 1 SMA. Both died before age two.
Under the pure genetic model the pattern requires a specific coincidence: both parents are heterozygous carriers of SMN1 deletion; on each conception, statistical draws produced three unaffected boys followed by two affected girls. The Mendelian probability is 1/4 per conception. The probability of three consecutive unaffected followed by two consecutive affected is (3/4)³ × (1/4)², approximately 2.6 percent. It is possible. It is not what a bystander should expect to see.
The pattern is exactly what an environmental shift between pregnancies would produce.
The mother spent ten years in the Navy as a flight surgeon.¹ Military medical personnel receive the standard occupational vaccine schedule: yellow fever, typhoid, hepatitis A, hepatitis B, meningococcal, influenza annually, tetanus boosters, MMR titers checked and additional injections given as needed, smallpox at deployment for many years, anthrax through and after the 1990s, plus deployment-specific injections that varied by posting. A Navy flight surgeon whose career overlapped the anthrax vaccine program received a burden well above the civilian norm, and one that continued to accumulate through her post-military practice years when the recommended adult schedule expanded further.
Aluminum, once injected, does not clear the way ingested aluminum clears. The gastrointestinal route absorbs approximately 0.1 percent of aluminum with rapid excretion. The intramuscular route produces approximately 100 percent absorption, with macrophages then distributing the metal throughout the body over months and years.⁷ Christopher Exley has documented the biopersistence of injected aluminum in specific tissues, including brain, decades after the injection.⁷ Yehuda Shoenfeld and colleagues have named the resulting clinical pattern ASIA syndrome, autoimmune/inflammatory syndrome induced by adjuvants, and the syndrome literature contains documented cases of motor neuron disease and motor neuron-adjacent syndromes following heavy occupational vaccination.
The three Peterson boys were born earlier in her career. The two Peterson girls were born later. Every additional injection between pregnancies added to a body burden that did not clear between them.
Aluminum crosses the placenta. Antonietta Gatti and Stefano Montanari documented undeclared metallic contamination in forty-three of forty-four vaccine products they examined, including aluminum salts, stainless steel particles, and lanthanide combinations.⁸ Richard Davidson and colleagues in 2024 confirmed the pattern in the newer product lines, identifying fifty-five undeclared chemical elements including all eleven heavy metals and twelve of the fifteen lanthanides.⁹ Whatever the mother carries at the time of conception, the fetus receives through the placental circulation. Whatever she metabolizes during pregnancy, the fetus metabolizes with a fetal blood-brain barrier and a fetal detoxification capacity, both incomplete.
The three-boys-then-two-girls pattern in a physician household with a Navy background is not a genetic coincidence. It is the household signature of a rising maternal body burden across a five-child span. The genetic framework absorbs the pattern as statistical draws from a fixed distribution. The terrain framework reads it as the household’s own natural experiment.
The essay on adult motor neuron disease published under this byline in May 2026 made the same argument for the adult version: family clustering that the establishment attributes to inherited genetic mutations is family clustering in a household with shared diets, shared household chemical exposures, shared dental amalgams, shared water sources, and shared vaccination schedules across decades.⁶ The “familial” cases are the households whose exposure profiles overlap most across generations. The “sporadic” cases are individuals whose profiles overlap most with the population baseline. In neither category has the establishment produced a control-group study comparing lifetime exposure histories between diagnosed patients and their unaffected siblings. That study, which would take a research team a year and cost a fraction of a single dose of the drugs the diagnosis now sells, has not been commissioned.
The Anterior Horn Cell
The cells that die in Kelly and Sarah are the cells that died in Lou Gehrig.
Motor neurons carry signals from the brain to the muscles. The upper motor neurons sit in the motor cortex of the brain. The lower motor neurons sit in the anterior horn of the spinal cord. The corticospinal tract connects them. In SMA, as in ALS, the anterior horn population degenerates, and in the pediatric case the loss dominates the presentation.¹⁰ The hands weaken. The arms waste. The legs follow. Feeding fails. Swallowing fails. The diaphragm, itself a muscle controlled by motor neurons in the cervical spinal cord, gives out. The patient dies because the muscle that pulls air into the lungs stops being told to do its job.
In the infant, this cascade compresses into months rather than years. The infant’s blood-brain barrier is not yet complete. The infant’s kidneys are not yet at adult filtration capacity. The infant’s liver has not yet developed the enzymatic pathways required to conjugate and clear the classes of toxin most abundant in the modern chemical environment. The infant is metabolically an open system. What enters the bloodstream reaches the central nervous system on a timeline the mature body would have partially defended against.
Christopher Shaw at the University of British Columbia demonstrated in 2009 what injected aluminum does to motor neurons.¹¹ His laboratory injected young male mice with weight-adjusted doses of the aluminum hydroxide adjuvant used in the American anthrax vaccine and compared them to saline controls. The aluminum-treated mice developed progressive motor dysfunction. Histological examination showed neuronal death in the motor neurons of the spinal cord and motor cortex. A second study documented aluminum located inside the motor neurons themselves. The paper’s title states its finding: *Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration.*¹¹
Shaw’s mice were adult males, weight-adjusted. Their blood-brain barriers were intact. Their livers were mature. What their motor neurons did with the injected aluminum is what a mature nervous system does. The infant nervous system, receiving the same class of substance through a schedule delivered when the barrier is incomplete, is exposed at concentrations Shaw’s model did not simulate, and to which the mature model was already vulnerable.
R.D. Lillie and colleagues at the National Institutes of Health published findings in 1944 and 1947 documenting that DDT exposure produced degeneration of the anterior horn cells of the spinal cord in animals.¹² These are the same cells. The mechanism by which a neurotoxin reaches the anterior horn is not chemical-specific. It is a matter of what crosses the barrier, what accumulates in the region, and what the affected cell’s clearance capacity is. The DDT finding was buried by the NIH. Shaw’s finding has been ignored by the pediatric vaccine safety literature. Both findings describe the same cell death. Both are documented. Neither has been used to frame the investigation of what kills anterior horn cells in a five-month-old.
Kelly’s Timing
Kelly Peterson developed symptoms in the four-to-five month window.¹ The American pediatric vaccine schedule she received had specific appointments at two months, four months, and six months. Each of these appointments delivered multiple aluminum-adjuvanted products in the same visit.
By the pre-2000 CDC schedule, an infant received approximately 3,925 micrograms of aluminum in the first eighteen months of life.¹³ After the pneumococcal conjugate vaccine (PCV7) was added to the schedule in February 2000 and hepatitis A followed, the cumulative aluminum load rose to approximately 4,925 micrograms in the same eighteen-month window.¹³ Kelly was born to a physician mother in private practice, a mother who would have followed the recommended schedule.
The two-month appointment in that era typically delivered DTaP (diphtheria-tetanus-acellular pertussis, aluminum-adjuvanted), Hib (some formulations aluminum-adjuvanted), IPV (inactivated polio vaccine), and hepatitis B (aluminum-adjuvanted). PCV7 was added to the two-month appointment as of February 2000. Depending on brand and formulation, the two-month appointment delivered aluminum in the range of several hundred micrograms in a single visit. The four-month appointment repeated most of these products, adding another comparable dose.
The Vaccine Adverse Event Reporting System (VAERS) database, examined for reports following the pneumococcal conjugate vaccine Synflorix from 2010 to 2024, produced a specific finding: hypotonia and hypotonic-hyporesponsive episodes appeared as new safety signals not previously listed in the product insert.¹⁴ Hypotonia, floppy infant syndrome, is the presenting sign of Kelly Peterson’s diagnosis. It is the presenting sign of Sarah Peterson’s diagnosis. The VAERS analysis identified it as a signal statistically associated with an aluminum-adjuvanted vaccine administered at the same two-month and four-month appointments that Kelly and Sarah received.
A separate VAERS analysis of 76,887 hepatitis B vaccine adverse event reports from 1990 to 2024 identified strongly disproportionate signals for musculoskeletal adverse events, with the authors attributing the pattern to chronic inflammatory responses induced by aluminum adjuvants and noting that aluminum cannot be effectively cleared from the body, producing cumulative effects in the skeletal and nervous systems.¹⁵
The establishment framework holds that Kelly Peterson’s anterior horn cells died because she inherited two deleted copies of SMN1. What the framework does not address is why the cells died between the two-month and four-month appointments in a child whose mother had followed the schedule delivered at those appointments. The SMN1 deletion, if present, would have been present since conception. The cell death was not. Something happened between the deletion the establishment measures and the cellular collapse it named after. What happened in that window is what the framework declines to examine.
Maternal Burden and the Sensitization Sequence
Charles Richet demonstrated in 1902 that injection of foreign material produces sensitization: with each subsequent exposure the response escalates. He received the Nobel Prize for the work in 1913.¹⁶ The mechanism was scrubbed from the pharmacological literature in the decades that followed, leaving only the appearance of what the establishment now calls autoimmunity. Richet had described the actual sequence: exposure, sensitization, escalating response, tissue damage.
Applied to the Peterson household, the sequence is a two-generation, two-stage exposure event.
Stage one: the mother receives a decade of occupational injections while serving as a Navy flight surgeon. Her body burden accumulates. Her tissues sensitize. Some fraction of the aluminum and undeclared metallic contamination from those injections biopersists in her body and continues to accumulate through her post-military practice years.
Stage two: three sons are born earlier in her exposure history, when her body burden is lower. She continues receiving occupational injections through her post-military years. Her fourth pregnancy, Kelly, arrives later. Her fifth pregnancy, Sarah, arrives later still. The maternal body carrying each fetus is not the same body. The tissue burden is higher. The placental transmission is higher. The fetus receives, through the placenta, whatever the mother’s tissues have not been able to clear.
Kelly is then born and receives the pediatric schedule at two months. The receiving nervous system was already sensitized in utero. What Kelly receives at two months is not the first injection. It is the additional dose in a sequence Richet described.
The mother’s own sensitization was not visible to her clinically. She was a functioning physician. She did not manifest the syndrome her tissues were accumulating toward, because her mature nervous system had defenses her infants did not. The pediatric outcome is what happens when a sensitized maternal body delivers a sensitized fetus into an infant vaccination schedule at the developmental window when the cells targeted have the least capacity to defend themselves.
The framework calls this “familial” SMA. The variable it names is SMN1 deletion. The variable it does not name is the multi-generational exposure sequence in which the deletion, if present, becomes lethal.
Sarah’s Reversal
The most instructive data point in the Peterson case is not what killed Sarah. It is what she did for six months before she died.
After Sarah’s diagnosis, her mother went on retreat with Father Zlatko Sudac in Croatia. She began a forty-day water fast. She removed herself from her normal environment, her normal diet, her normal work stresses, her normal daily exposures. She prayed intensively. In her testimony she describes this period as the point at which she asked for Sarah’s healing after having previously declined to pray for it.²
She returned home. Within days, Sarah kicked her. Sarah, who had not moved her legs in months, moved. Over the following six months Sarah gained strength. She moved her arms. She began sitting up. She began taking solid food. She substantially reversed the motor deficits by which the diagnosis was defined.
The medical model reads this as delayed disease progression that was always going to happen. The narrative absorbs the reversal into the “variable severity” clause and does not investigate what triggered the six-month upswing. The framework does not investigate because within its own terms, SMN1 deletion is a fixed molecular fact that cannot be reversed by anything the mother did. The reversal, by that logic, must be dismissed as coincidence.
The terrain framework reads the same data as an intervention experiment. What the mother did was, in terrain terms, exactly what the terrain model prescribes for early motor neuron injury. She fasted, which cleared metabolic burden and redirected the body’s energy from digestion to repair. She removed daily household toxin exposure by leaving her environment. She reduced stress physiology by leaving her practice. And she was breastfeeding Sarah at least intermittently during this period. Whatever crossed to Sarah through the milk was, for the first time, milk from a mother in reduced-toxin, reduced-stress, fasting-repair mode.
Herbert Shelton documented multiple sclerosis recoveries through extended water fasting in cases conventional neurology had categorized as hopeless.¹⁷ His mechanism was straightforward: clear the toxic burden, allow the body to redirect energy from digestion to repair, sunbathe, rest. His qualification also holds. Full recovery, Shelton wrote, is possible in the initial stage, not in the advanced stages when irreversible changes have taken place. Sarah was in the initial stage. Her mother was doing, for the wrong reason, exactly what Shelton would have prescribed for the right one.
Sarah then declined over the following six months and died. The testimony does not detail what happened at the turning point, but the pattern of decline in these cases is not spontaneous. It tracks with resumed exposure, hospitalization, feeding tube placement, and the pharmaceutical management of decline. The initial insult produced the deficit. The intervention resumed the trajectory. The diagnosis absorbed both as one continuous “progression.”
The mother read Sarah’s six-month improvement as a miracle initiated and then revoked by God. The medical establishment reads it as coincidence within variable disease severity. The terrain framework reads it as terrain change producing predictable improvement, followed by terrain reversion producing predictable decline. Of the three readings, only the last is testable, and the terrain framework predicts, and Shelton’s Hygienic tradition documented, that other children in Sarah’s condition would respond to the same intervention in the same direction.
Under no framework is Sarah’s six-month upswing evidence that SMN1 deletion causes progressive death of motor neurons on a fixed molecular schedule. Under a genetic determinism framework the upswing should not have happened. Under the terrain framework it did what the model predicts.
The Pharmaceutical Response
Between 2016 and 2025, four drugs were approved to treat SMA. Each of them intervenes at some level of the SMN1/SMN2 story. None of them addresses the exposures that produced the cell death in the first place.
Nusinersen (Spinraza), approved by the FDA in December 2016 and marketed by Biogen, is an antisense oligonucleotide administered by intrathecal injection into the spinal fluid.¹⁸ Six loading doses in the first year, three maintenance doses per year thereafter, for the life of the patient. The 2016 list price was $125,000 per injection. First-year cost: $750,000. Every subsequent year for life: $375,000. A patient maintained on Spinraza from infancy to age forty would generate approximately $15 million in revenue for Biogen.
Onasemnogene abeparvovec (Zolgensma), approved by the FDA in May 2019 and marketed by Novartis, is a one-time intravenous infusion delivering what Novartis calls a functional SMN1 gene inside what the sponsor markets as an adeno-associated viral vector.¹⁹ The list price at launch was $2.125 million per dose. Novartis has publicly stated it considered pricing the therapy near $5 million. The Institute for Clinical and Economic Review reviewed the pricing and concluded it was cost-effective within the upper bound of its benchmark range.
Risdiplam (Evrysdi), approved by the FDA in August 2020 and marketed by Genentech and Roche, is a daily oral liquid that modifies SMN2 splicing.²⁰ Priced by patient weight, capped at $340,000 per year once the patient reaches 44 pounds, typically age six. A lifetime patient generates a comparable revenue stream to Spinraza on a lower per-year basis.
Itvisma, approved by the FDA in November 2025, is an intrathecal formulation of the same active molecule as Zolgensma marketed for older SMA patients. List price: $2.59 million per single-dose administration.²¹
In the nine years between Spinraza’s approval and Itvisma’s, the global SMA drug market grew from zero to several billion dollars per year. Novartis paid approximately $12 billion for Avidity Biosciences in late 2025 to expand its neuromuscular pipeline. The genetic explanation for SMA, that the disease arises from an inherited deletion of SMN1, supports every pricing model in this market. The alternative explanation, that toxin exposure kills anterior horn cells in vulnerable infants, would support no pricing model. The market has a strong economic reason to prefer the genetic explanation.
The clinical results deserve scrutiny. Spinraza’s original ENDEAR trial in symptomatic infants was terminated early on the basis of interim results reported as favorable. A 2024 EudraVigilance safety review by Belančić and colleagues documented ongoing adverse events across all three approved drugs, including post-lumbar puncture syndrome, liver toxicity, elevated troponin, and respiratory reactions.²² The children maintained on these drugs are living longer than the historical natural-history cohort of the untreated 1990s. Whether they are living better, and whether the “disease” being modified is the same disease that killed Kelly and Sarah, is a question the framework does not admit is open.
The treatment Novartis markets as gene therapy delivers what the sponsor calls a functional SMN1 copy inside what the sponsor calls an adeno-associated virus vector. The delivery particle is the same category of injected foreign material that Richet was describing in 1902. The single dose is not, mechanistically, a single event. It is a persistent presence of injected biological material in the tissue, producing whatever the sponsor's protocol makes it produce, plus the aluminum-adjuvanted childhood schedule the child continues to receive, plus the accumulated background of everything else the child is exposed to over a lifetime. The measurable improvement compared to untreated natural history is what the sponsor reports. Whether the intervention reverses the underlying toxin injury or delays how it manifests is a question the sponsor did not design the trials to answer.
Every one of these drugs is priced at a level that assumes the disease is genetic, incurable without pharmaceutical intervention, and destined to be a lifetime financial dependency. The one intervention Cyndi Peterson accidentally ran on Sarah, remove exposures, rest, fast, feed the repair process, is not on any of the four labels.
What Can Be Done
The terrain framework offers an actionable response where the establishment offers a diagnostic verdict and a $2.59 million price tag. The interventions below proceed from the principle that the body is built to repair itself when the insults stop and the repair substrate is present, and that a very young child in the earliest stages of anterior horn cell injury has the best chance of any patient on the motor neuron disease spectrum.
For a family with an affected child, the priority is stopping the additional insults. No further injections. Every injection between diagnosis and death added to the burden of undeclared metallic contamination in tissues that were already showing the cellular consequence. Audit every pharmaceutical intake for anticholinergic activity, blood-brain barrier crossing, and neurological side effects. Remove environmental sources of aluminum, mercury, and organophosphate exposure to the extent possible: filtered water, organic food, glass and stainless steel storage, elimination of synthetic fragrance and personal-care product load. Assess dental exposures for both parents if amalgams are present.
For the child specifically: nutrient-dense whole foods when developmentally appropriate, breast milk from a mother who is herself undergoing the same terrain intervention, pasture-raised animal products and bone broth as tolerated, sunlight on skin daily, and above all the removal of the specific inputs the terrain framework identifies as anterior-horn-cell-lethal. Herbert Shelton’s fasting protocol is not directly applicable to an infant, but the principle underlying it, clear the burden and redirect energy to repair, is applicable through maternal fasting during breastfeeding, careful attention to the child’s exposure to the specific substances that damage motor neurons, and support of the child’s own metabolic clearance pathways through nutrition.
For families at risk who have not yet had an affected child: the household control-group logic applies. If both parents have been told they carry the deletion the establishment measures, the environmental question becomes acute. Any additional injection between pregnancies raises the risk that the mother’s rising body burden will be the variable that flips a manageable exposure profile into an unmanageable one. Genetic counseling framed as “you have a one-in-four chance per pregnancy” is precisely wrong: the risk is not fixed. It is dynamic, and it rises with cumulative maternal exposure.
For clinicians willing to look, the physician household is a natural experiment. Two physicians. Five children. Three unaffected boys born earlier in the mother’s exposure history. Two affected girls born later. The medical record contains the vaccination history, the diagnosis dates, and the household exposure profile. What the record does not contain is the analysis that would test whether the boys-then-girls pattern tracks with the mother’s cumulative body burden. That analysis has never been done because within the genetic framework there is nothing to analyze.
Not all cases recover. The earlier the intervention, the better. Shelton’s principle holds: the inflammatory stage is remediable; the late hardening is not. By the time the diagnosis arrives in a Type 1 SMA infant, weeks of the child’s short life have already been refused to repair. This is the cruelty embedded in the framework’s delay. The reader who has just heard the diagnosis has less time than the mother who acts in response to a family history or a personal exposure profile before conception.
The Three Brothers
The Peterson family contains its own control group. Three boys, born before their mother’s body burden reached the level at which it produced the pediatric outcome, are alive and healthy today. Two girls, born after their mother’s burden reached that level, are dead.
The establishment framework absorbs the pattern as a coincidence of Mendelian draws. Under that framework, the boys are lucky and the girls are unlucky, and no further inquiry is warranted. The framework declines to examine why the girls’ anterior horn cells died at four to five months while their brothers’ anterior horn cells never developed a symptom. It declines because the framework was constructed around a molecular deletion, not around the biological question of what specifically kills those specific cells in that specific developmental window.
The terrain framework reads the same pattern as a household experiment with three controls and two exposed cases. Under that framework, the boys are the invisible study arm. Their existence is the piece of evidence that the framework cannot admit because admitting it would require asking why they are alive.
Cyndi Peterson accepted the diagnosis her medical training required her to accept. She built a spiritual framework on top of it that gave her the meaning her medical framework could not. Her testimony is worth reading because everything in it is documented, and the documentation includes the pieces the diagnosis did not use. The three healthy brothers. The Navy flight surgeon career. The physician household. Kelly’s onset in the four-to-five month window. Sarah’s six months of clinically visible reversal during her mother’s forty-day fast. These are not incidental features of the case. They are the case.
The girls died. That is documented. The girls died of a genetic disorder. That is a story built on top of that fact using a framework that has an economic incentive to prefer that story over any other. The three older brothers are still alive.
How To Explain It To A 6 Year Old
Motor neurons are wires that carry messages from your brain to your muscles. They tell your hand to wave and your leg to walk. In this disease the wires stop working when the baby is very small, sometimes before the baby is one year old. The messages cannot get through. The baby cannot lift her head or move her arms or legs. After a while she cannot breathe.
Doctors say it happens because of one broken piece inside the baby’s cells that came from the mummy and the daddy. They say the baby was born that way and nothing can be done.
Some things doctors do not talk about are true too. Babies get lots of shots when they are very small, one at two months old and another at four months old. These shots have small amounts of metal in them. The metal does not go away. In some babies the metal hurts the same wires that this disease breaks.
Some mummies have lots of shots before the baby is born, especially if the mummy is a doctor or a soldier. The metal from those shots stays inside the mummy for years. Some of it goes across into the baby before the baby is born.
There was a mummy in America who was a doctor and used to be in the Navy. She had five children. Her first three children were boys and they are all fine. Her fourth and fifth children were girls, and both of them got this disease and died before they were two.
Doctors said the girls were unlucky. But her three older boys were the same mummy’s babies. Something changed between the boys and the girls. What changed was how much the mummy had inside her body.
If a baby gets this disease, the most important thing is to stop putting anything new in. Give the baby real food when she is old enough. Keep her in the sunshine. Let her rest. Do not put anything in her mouth or arm that does not need to be there. The body wants to fix itself. Stop hurting it and give it a chance.
References
Peterson C. Testimony recorded at Medjugorje, 2025. Interview with Tomislav Vlasic, published on Mary TV. Peterson describes her Navy service as a flight surgeon, her medical practice, the birth order of her five children, Kelly Peterson’s symptom onset at approximately four to five months, and the diagnostic sequence delivered by her pediatric neurologist. The neurologist’s stated carrier frequency of 1 in 80 is Peterson’s recollection; the establishment-cited range is 1 in 40 to 1 in 60.
Peterson C. Testimony recorded at Medjugorje, 2025. Peterson’s account of Sarah’s clinical strength at birth relative to her three brothers, the contaminated first blood sample and the subsequent heel-stick confirmation of homozygous SMN1 deletion, the forty-day water fast on the Sudac retreat, Sarah’s clinically visible six-month strengthening, and her subsequent six-month decline to death at approximately twenty-one months.
Nurputra DK, Lai PS, Harahap NI, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Annals of Human Genetics. 2013;77(5):435–463. Werdnig 1891 and Hoffmann 1893 origin references; Kugelberg and Welander 1956 for later-onset classification.
Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165. The Melki laboratory paper identifying SMN1 as the deleted gene in the majority of clinical SMA cases.
Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Archives of Neurology. 2011;68(8):979–984. Establishes the “second most common fatal autosomal recessive disorder after cystic fibrosis” framing and the standard incidence and carrier-frequency figures. See also Prior TW. Perspectives and diagnostic considerations in SMA. Genetics in Medicine. 2010;12(3):145–152.
Unbekoming. What Is Motor Neuron Disease? An Essay on Lou Gehrig’s Disease, Anterior Horn Cells, and the Streetlight They Were Killed Beneath. Lies are Unbekoming, 20 May 2026. Sections on the “familial” versus “sporadic” foreclosure and the household-clustering interpretation apply directly to the pediatric case.
Exley C. The toxicity of aluminium in humans. Morphologie. 2016;100(329):51–55. See also Shoenfeld Y, Agmon-Levin N. “ASIA” — Autoimmune/inflammatory syndrome induced by adjuvants. Journal of Autoimmunity. 2011;36(1):4–8. And Unbekoming. Negative Synergies: An Essay on Where Injected Metal Meets Modern Life. Lies are Unbekoming, 8 July 2026, for the biopersistence and placental transfer discussion.
Gatti AM, Montanari S. New quality-control investigations on vaccines: micro- and nanocontamination. International Journal of Vaccines and Vaccination. 2017;4(1):7–14.
Davidson RM, Broudy D, Yanowitz S, Santiago D, Oller JW Jr. True or False? At Least 55 Undeclared Chemical Elements Have Been Detected by ICP-MS in COVID-19 “Vaccines.” International Journal of Vaccine Theory, Practice, and Research. 2024;3(2):1394.1–1394.27.
Boido M, Vercelli A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Frontiers in Neuroanatomy. 2016;10:6.
Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. Journal of Inorganic Biochemistry. 2009;103(11):1555–1562.
Lillie RD, Smith MI. Pathology of experimental poisoning in cats, rabbits, and rats with 2,2-bis(parachlorphenyl)-1,1,1-trichlorethane. Public Health Reports. 1944;59(31):979–984. See also Biskind MS. Public health aspects of the new insecticides. American Journal of Digestive Diseases. 1953;20(11):331–341.
Miller NZ. Aluminum in childhood vaccines is unsafe. Journal of American Physicians and Surgeons. 2016;21(4):109–117. The pre-2000 (3,925 mcg) and post-2000 (4,925 mcg) cumulative-aluminum figures for the eighteen-month schedule are derived from CDC-published aluminum content per product across the recommended schedule of the period.
Wang J, Sun M, Liu Y, et al. Adverse events following Synflorix vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 2010–2024. Analysis identifying hypotonia and hypotonic-hyporesponsive episodes as newly detected safety signals not previously listed in the product insert.
Wei Z, Chen L, Liu J, et al. Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system. 76,887 VAERS reports 1990–2024. The aluminum adjuvant slow-release and cumulative-effect attribution is stated in the paper’s own conclusions.
Richet C. Anaphylaxis. Nobel Lecture, 11 December 1913. Nobel Foundation.
Shelton HM. Fasting Can Save Your Life. American Natural Hygiene Society. Chapter 20 on multiple sclerosis recoveries under extended therapeutic fasting.
Palmer E. Biogen’s $375K Spinraza price puts a Sovaldi-style spotlight on rare disease meds. Fierce Pharma. 6 January 2017. Pricing confirmed against Institute for Clinical and Economic Review reports and against buyandbill.com J-code J2326 reimbursement data updated April 2026.
Cross R. Novartis gets okay for SMA gene therapy, with $2m price tag. Pharmaphorum. 28 May 2019. Confirmed against Fierce Pharma and BioPharma Dive coverage of Zolgensma launch pricing.
Blankenship K. FDA Approves Evrysdi, Third Drug for Spinal Muscular Atrophy. Managed Healthcare Executive. 7 August 2020. Confirmed against Genentech pricing statement and Fierce Pharma competitive analysis.
Liu A. Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M. Fierce Pharma. 24 November 2025. Itvisma intrathecal formulation of onasemnogene abeparvovec.
Belančić A, et al. Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union. 2024 EudraVigilance analysis of nusinersen, onasemnogene abeparvovec, and risdiplam adverse event reporting trends.
Additional Sources
Cure SMA. The Discovery of SMA. curesma.org.
Chen X, Sanchis-Juan A, French CE, et al. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. International Journal of Molecular Sciences. 2023.
Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy. American Journal of Medical Genetics Part A. 2010;152A(7):1608–1616.
American College of Obstetricians and Gynecologists. Carrier Screening for Spinal Muscular Atrophy (SMA). acog.org.
Cowan TS, Fallon Morell S. The Contagion Myth. Skyhorse Publishing, 2020.
Lester D, Parker D. What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. Independently published, 2019.
Truth Be Told: I’ve Accepted an Invitation to Speak on The Unvaccinated
On September 17th, I’ll be giving a one-hour presentation titled The Unvaccinated as part of a six-hour livestream called Truth Be Told. This is the first time I have accepted an invitation to an event, and I have been honoured with the opening act. The livestream begins at 12pm EST.
Vaccination is the subject closest to my heart, and this is another opportunity to spread the word. The format will preserve the pen name.
Tickets are here.
The code UNBEKOMING is $5 off and applies automatically at that link. Replay available afterwards. Hope you can make it.
The only thing this essay neglects is the role the father plays. From what I understand the health of the placenta is greatly influenced by the health of the father who the article states was also a physician presumably carrying a substantial toxic load in adherence to vaccine schedules. It takes two to tango in creating a child, so to speak, why leave his role out of it?